Condor Capital Management’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Condor Capital Management’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,030	Closed	-$20K	–	417
2022 Q3	$20K	Hold	2,030	–	–	﹤0.01%	377
2022 Q2	$20K	Sell	2,030 -350	-15%	-$3.45K	﹤0.01%	363
2022 Q1	$23K	Hold	2,380	–	–	﹤0.01%	321
2021 Q4	$24K	Hold	2,380	–	–	﹤0.01%	288
2021 Q3	$24K	Hold	2,380	–	–	﹤0.01%	255
2021 Q2	$24K	Hold	2,380	–	–	﹤0.01%	250
2021 Q1	$23K	Buy	+2,380	New	+$23.8K	﹤0.01%	244

Other funds holding IBER.U

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

TAM

Terrapin Asset Management Miami, Florida $87.8M AUM 16.84% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Condor Capital Management's IBER.U Position: Q4 2022 in Review

Condor Capital Management sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q4 2022, closing a stake of 2,030 shares — an estimated $20K sold.

Condor Capital Management first reported a position in IBER.U in Q1 2021 and held it in 7 quarters. The position peaked at $24K in Q4 2021. 10 funds tracked by Wall St. Rank hold IBER.U as of Q4 2022.

Condor Capital Management reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q4 2022 after selling out during the quarter.
Condor Capital Management sold 2,030 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q4 2022, an estimated $20K.
Condor Capital Management first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 7 quarters.
Condor Capital Management's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $24K in Q4 2021.
10 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q4 2022.

Based on Condor Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.